Delta Financial Group’s Esperion Therapeutics ESPR Stock Holding History

Delta Financial Group’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$40K	Sell	23,150 -200	-0.9%	-$369	0.01%	257
2024 Q4	$51K	Buy	23,350 +1,600	+7%	+$3.73K	0.01%	249
2024 Q3	$36K	Sell	21,750 -1,200	-5%	-$2.42K	0.01%	137
2024 Q2	$51K	Sell	22,950 -300	-1%	-$706	0.02%	121
2024 Q1	$62K	Hold	23,250	–	–	0.02%	233
2023 Q4	$70K	Buy	23,250 +100	+0.4%	+$130	0.02%	218
2023 Q3	$23K	Hold	23,150	–	–	0.01%	206
2023 Q2	$32K	Hold	23,150	–	–	0.04%	85
2023 Q1	$37K	Sell	23,150 -200	-0.9%	-$1.03K	0.01%	180
2022 Q4	$137K	Buy	+23,350	New	+$167K	0.06%	169

Other funds holding ESPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PCM

PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Delta Financial Group's ESPR Position: Q1 2025 in Review

Delta Financial Group reduced its Esperion Therapeutics (ESPR) stake by 0.86% in Q1 2025, selling an estimated $369 and leaving 23,150 shares worth $40K. The position accounts for 0.01% of the portfolio, ranked #257.

Delta Financial Group first reported a position in ESPR in Q4 2022 and has held it in 10 quarters since. The position peaked at $137K in Q4 2022. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

Delta Financial Group held 23,150 shares of Esperion Therapeutics worth $40K as of Q1 2025.
Delta Financial Group sold 200 Esperion Therapeutics shares in Q1 2025, an estimated $369.
Esperion Therapeutics made up 0.01% of Delta Financial Group's portfolio in Q1 2025, its #257 holding.
Delta Financial Group first reported a position in Esperion Therapeutics in Q4 2022 and has held it in 10 quarters since.
Delta Financial Group's Esperion Therapeutics position peaked at $137K in Q4 2022.
186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on Delta Financial Group's 13F filing for Q1 2025, filed 9 May 2025.